Viral Features of Lamivudine Resistant Hepatitis B Genotypes A and D

Hepatology

Volumn 39, Issue 1, 2004, Pages 42-50

  Zöllner, Bernhard ^a,d   Petersen, Jörg ^a   Puchhammer Stöckl, Elisabeth ^b   Kletzmayr, Josef ^c   Sterneck, Martina ^a   Fischer, Lutz ^a   Schröter, Matthias ^a   Laufs, Rainer ^a   Feucht, Heinz Hubert ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; MUTANT PROTEIN; RNA DIRECTED DNA POLYMERASE; HEPATITIS B CORE ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIBIOTIC RESISTANCE; COHORT ANALYSIS; DRUG EFFECT; GENETICS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 1442355394     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20016     Document Type: Article

References (39)

1. Lai CE, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
2. Dienstag JL, Schiff ER, Wright TL, Perillo PR, Hann HWL, Goodman Z, Crowther L, et al. for the U.S. Lamivudine Investigator Group. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
3. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
4. Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long-term therapy of chronic hepatitis B with lamivudine. HEPATOLOGY 2000;32:828-834.
5. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180.
6. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, et al. Three year lamivudine therapy in chronic HBV [abstract]. J Hepatol 1999;30(Suppl 1):59.
7. Chang TT, Lai CL, Liaw YF, Guan R, Lira SG, Lee CM, Ng KY, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstract]. Antivir Ther 2000;5(Suppl 1):44.
8. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. HEPATOLOGY 2001;34:583-589.
9. Zöllner B, Schäfer P, Feucht HH, Schröter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-663.
10. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lira SG, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001;33:1527-1532.
11. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. HEPATOLOGY 1999;30:567-572.
12. Honkoop P, de Man RA, Niesters HGM, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998;29:510-511.
13. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartat-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy, Clin Infect Dis 2001;33:403-405.
14. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. HEPATOLOGY 1998;25:628-633.
15. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai CL, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients [abstract]. HEPATOLOGY 1998;28:319A.
16. Lai CL, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C, Brown N, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with cronic hepatitis B. Clin Infect Dis 2003;36:687-696.
17. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
18. Zöllner B, Petersen J, Schäfer P, Schröter M, Laufs R, Sterneck M, Feucht HH. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-1277.
19. Zöllner B, Petersen J, Schröter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in the risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-935.
20. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
21. Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection method. HEPATOLOGY 2000;32:626-629.
22. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R, The Eurohep Pathobiology Group. Quantitative detection of Hepatitis B virus DNA in two international reference plasma preparations. J Clin Microbiol 1999;37:68-73.
23. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. HEPATOLOGY 2001;33:751-757.
24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLJ, Brown N, for the Lamivudine Clinical Trial Group, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. HEPATOLOGY 1998;27:1670-1677.
25. Norder H, Hammas B, Löfdahl S, Couroucé AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992;73:1201-1208.
26. Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001;17:1244-1245.
27. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. HEPATOLOGY 2000;32:1163-1169.
28. Zöllner B, Stoehr A, Plettenberg A, Feucht HH, Schröter M, Schäfer P, Laufs R. In vivo dynamics and pathogenicity of wild-type and resistant hepatitis B virus during long-term lamivudine monotherapy-a clinical note. J Clin Virol 2000;17:183-188.
29. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
30. Gutfreund K, Williams M, George R, Bain VG, Ma MM, Yoshida EM, Villeneuve JP, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469-475.
31. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. HEPATOLOGY 2002;36:219-226.
32. Chen YC, Delbrook K, Dealwis C, Mimms L, Mushawar IK, Mandecki W. Discontinous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 1996;93:1997-2001.
33. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S, Fyfe J, et al. Reduced antigenicity of the hepatitis B protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313.
34. Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998;5:241-248.
35. Chen RYM, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. HEPATOLOGY 2003;37:27-35.
36. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33:430-439.
37. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-1280.
38. Tillmann HL, Trautwein C, Bock T, Böker KHW, Jäckel E, Glowienka M, Oldhafer K, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulion after liver transplantation. HEPATOLOGY 1999;30:244-256.
39. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002;16:131-133.